

# Don't Hesitate to Treat Possible Kawasaki Disease

BY NANCY WALSH  
New York Bureau

NEW YORK — Physicians should never feel guilty about overdiagnosing and overtreating possible Kawasaki disease, Dr. Jeffrey R. Starke said at a meeting sponsored by the American College of Emergency Physicians.

"If you look at the risk-benefit ratio of treatment versus the complications if we don't treat, it's clear we should err on the side of overtreatment, especially in children younger than 12 months who are at high risk for developing severe coronary artery abnormalities," Dr. Starke stated.

These youngest patients also are more likely to present with incomplete Kawasaki disease, and this diagnosis should be considered in any infant younger than 6 months with fever persisting for more than 6 days who has evidence of systemic inflammation that cannot be otherwise explained.

The diagnosis of incomplete Kawasaki disease also should be considered in children with unexplained fever for more than 5 days who have two or three, rather than four, of the principal clinical features of Kawasaki disease (see box below).

In such a patient, if the C-reactive protein is 3 mg/dL or greater and/or the erythrocyte sedimentation rate is 40 mm/hour or more, supplemental laboratory criteria should be obtained.

If three or more of the supplemental laboratory criteria are present, the child should have an echocardiogram and treatment should begin.

If there are fewer than three of the supplemental laboratory criteria, an echocardiogram is in order.

If the echocardiogram shows evidence

of cardiac abnormalities, start treatment. If it is negative and the fever abates, Kawasaki disease is unlikely.

But if it persists, repeat the echo and arrange for a consultation with an infectious disease or rheumatology expert, said Dr. Starke, vice chairman of pediatrics at Baylor College of Medicine, Houston.

Another reason for instituting treatment, even if the diagnosis is incomplete or uncertain, is that the standard treat-

ment with intravenous immunoglobulin (IVIG), 2 g/kg as a single infusion, is quite safe.

"It's expensive, but the complication rate is pretty darn low," he said.

On occasion, treatment can even begin before an echocardiogram is done.

"In my hospital, it's virtually impossible to get an echo between Friday afternoon and Monday morning, and if we are convinced the child has Kawasaki disease, we'll go ahead and give the IVIG

and get the echo later," he said.

Aspirin also is routinely given, even though a recent Cochrane review found insufficient evidence supporting this practice (Cochrane Database Syst. Rev. 2006;doi:10.1002/14651858.CD004175.pub2).

"I don't know of a single infectious disease expert or rheumatologist who doesn't still use aspirin in addition to IVIG in the treatment of Kawasaki disease," Dr. Starke commented.

High aspirin doses of 80-100 mg/kg per

## 25,616 Cases of Pertussis Reported in 2005<sup>1</sup> Prevent Them

### The Criteria for Kawasaki Disease

#### Diagnostic Criteria

Fever greater than 39°C for 5 days, plus four of the following:

- ▶ Conjunctivitis, usually bulbar and bilateral.
- ▶ Mucous membrane changes, such as redness and cracking.
- ▶ Rash, either generalized or local.
- ▶ Enlarged cervical lymph nodes, usually unilateral and nontender.
- ▶ Peripheral changes, such as swelling or peeling.

#### Incomplete Kawasaki Supplemental Laboratory Criteria

- ▶ Albumin 3 g/dL or less.
- ▶ Anemia for age.
- ▶ Elevation of alanine aminotransferase.
- ▶ Platelets 450,000/mcL or more after 7 days.
- ▶ White blood cell count 15,000/mcL or higher.
- ▶ Urine white blood cell count 10/HPF (high power field) or more.

Sources: Dr. Starke; *Circulation* 2004;110:2747-71

#### Indications and Usage

DAPTACEL vaccine is indicated for the active immunization of infants and children 6 weeks through 6 years of age (prior to 7th birthday) for the prevention of diphtheria, tetanus, and pertussis (whooping cough). DAPTACEL vaccine is recommended for administration as a 4-dose series at 2, 4, 6, and 17 to 20 months of age. The interval between the 3rd and 4th dose should be at least 6 months. It is recommended that DAPTACEL vaccine be given for all doses in the 4-dose series because no data on the interchangeability of DAPTACEL vaccine with other DTaP\* vaccines exist. As with any vaccine, vaccination with DAPTACEL vaccine may not protect 100% of individuals.

#### Safety Information

There are risks associated with all vaccines. Local and systemic adverse reactions to DAPTACEL vaccine may include redness, swelling, or tenderness at the injection site, fever, irritability, and drowsiness. Other local and systemic adverse reactions may occur. DAPTACEL vaccine is contraindicated in persons with a hypersensitivity to any component of the vaccine. In addition, it is contraindicated in persons with any immediate anaphylactic reaction or encephalopathy not attributable to another identifiable cause after a previous dose of DAPTACEL vaccine. Because any intramuscular injection can cause injection site hematoma, DAPTACEL vaccine should not be given to persons with any bleeding disorder, such as hemophilia or thrombocytopenia, or to persons on anticoagulant therapy unless the potential benefits clearly outweigh the risk of administration. If the decision is made to administer DAPTACEL vaccine to such persons, it should be given with caution, with steps taken to avoid the risk of hematoma formation following injection.

Before administering DAPTACEL vaccine, please see brief summary of full Prescribing Information on following page.

**References:** 1. Centers for Disease Control and Prevention (CDC). Notice to readers: final 2005 reports of notifiable diseases. *MMWR*. 2006;55(32):880-890. 2. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. *N Engl J Med*. 1996;334:349-355. 3. Gustafsson L, Hallander H, Olin P, Reizenstein E, Storsaeter J. Efficacy trial of acellular pertussis vaccines: technical report trial I with results of preplanned analysis of safety, efficacy and immunogenicity. Stockholm, Sweden: Swedish Institute for Infectious Disease Control; 1995. Contract N01-AI-15125. 4. WHO meeting on case definition of pertussis: Geneva, 10-11 January 1991; Geneva, Switzerland: World Health Organization, 1991:4-5. Issue MIM/EPI/PERT/91.1.

day should be given initially. Some clinicians continue the high dose for 14 days and then reduce the dose to 3-5 mg/kg per day, while other practitioners maintain the high dose only until 24-48 hours after the patient defervesces, and then switch to the low dose for 2 months for antiplatelet effects.

There have been no trials suggesting the superiority of either approach, he noted. Nor is there convincing evidence for adding corticosteroids to the treatment regimen, although data suggest some clinical benefit.

In a recent prospective randomized trial that included 178 patients with Kawasa-

ki disease, children who received prednisolone in conjunction with IVIG had a shorter duration of fever and a faster fall in C-reactive protein, but there was no difference in coronary artery dilation at 1 month (J. Pediatr. 2006;149:336-41), Dr. Starke noted


If the fever persists or returns more than 36 hours after completion of the IVIG infusion, a second dose can be given. "But be patient. It's very common for kids to continue to run a fever the day after you give the IVIG dose, even as other symptoms are improving," Dr. Starke advised. Most patients respond very well to that second dose, he added. ■

# Pediatric News



is the best-read publication among office- and hospital-based pediatricians.

Thanks For Making Us



Source: Focus™, December 2006, Office and Hospital Pediatricians, Projected Average Issue Readers, Table 1001

**sanofi pasteur**

The vaccines business of sanofi-aventis Group

CPT\* Code: 90700



## DAPTACEL®

Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed

Protects Against All Severities of Pertussis

### Count on a broad range of protection

- **78%** efficacy against all severities of pertussis:  $\geq 1$  day of cough with laboratory-confirmed pertussis<sup>2,3</sup>
- **85%** efficacy against severe/WHO<sup>†</sup>-defined pertussis:  $\geq 21$  days of consecutive paroxysmal cough with culture or serologic confirmation or contact with a confirmed case<sup>2,4</sup>

Available through your VFC<sup>§</sup> provider

To order DAPTACEL vaccine, log onto [www.vaccineshoppe.com](http://www.vaccineshoppe.com) or call 1-800-VACCINE (1-800-822-2463). Please visit [www.DAPTACEL.com](http://www.DAPTACEL.com)

\* DTaP = Diphtheria, tetanus, and acellular pertussis;

† CPT is a registered trademark of the American Medical Association;

‡ WHO = World Health Organization;

§ Vaccines for Children.

DAPTACEL vaccine is manufactured by Sanofi Pasteur Limited and distributed by Sanofi Pasteur Inc.